NEW YORK, Jan. 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
IntroductionAs branded angiotensin receptor blockers (ARBs) lose market exclusivity, fixed-dose combinations become the only remaining products able to generate growth in the antihypertensives market. However, they will not be able to do enough to prevent market erosion which will fall from $37.5 billion in 2009 to $28.6 billion in 2019 at -3% CAGR.
Features and benefits
* Analysis of revenue and volume sales of antihypertensive drug classes in the seven major markets* Assess the impact of key patent expiries, such as Merck & Co's Cozaar and Hyzaar* Forecast antihypertensive revenue and volume sales to 2019, including performance of developmental agents* Understand the impact of clinical trials and pipeline agents on future market dynamics
HighlightsThe first triple drug combination; Exforge HCT (valsartan + amlodipine + hydrochlorothiazide) has reached the US market. Valturna (aliskiren + valsartan; Novartis) has combined the direct renin inhibitor aliskiren with the ARB valsartan to become the first drug to offer dual blockade of the renin angiotensin system.The only innovative antihypertensive agent expected to launch by 2019 is Takeda's ARB; azilsartan medoxomil (TAK-491). Launching in this time frame will make azilsartan an extremely late entry to the ARB class and the drug is going to experience of number of resistors to success.Japan has seen a number of recent launches of ARB combinations. If the new launches replicate the success of Hyzaar (launched in 2006) and Japanese physicians accept the ARB + CCB (calcium channel blocker) combination this will represent the strongest opportunity for class growth in the seven major markets.
Your key questions answered* Quantify and qualify antihypertensive sales in each of the seven major markets for 2006–2019* Examine the future performance of leading antihypertensive brands and how the growth of generics will impact revenues* Understand challenges faced by pipeline agents and new fixed-dose-combinations
To order this report:: Forecast Insight: Antihypertensives - Fixed-dose combinations fail to offset generic erosion
Copyright©2010 PR Newswire.
All rights reserved